ClinicalTrials.gg
RecruitingNCT05648097Updated Dec 6, 2023

Baldachin: Ceiling HEPA-filtration to Prevent Nosocomial Transmission of COVID-19

An interventional study of Baldachin in COVID-19, sponsored by Insel Gruppe AG, University Hospital Bern. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2023-12-06.

Sponsored by Insel Gruppe AG, University Hospital Bern · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
104
Allocation
Non-randomized
Ages
18 Years to 120 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 97 studies in COVID-19 with a site in Switzerland — 6 open to participants now, 10 under way, 1 of them phase 3. COVID-19 · Switzerland.

Planned enrollment
24th of 49
104 · median 100
Started
2023
with 6 others
No phase
16 of 97
3 open now
Registered
83rd of 97
by date
Lead sponsor
9 of 97
Insel Gruppe AG, University Hospital Bern

Among the 97 studies in COVID-19 with a site in Switzerland, this one is the 24th largest by planned enrollment of the 49 interventional ones that give a count, is one of 7 that started in 2023, is one of 16 with no phase, and was the 83rd registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

6 of the 97 studies in COVID-19 with a site in Switzerland are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 120 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 97 studies in COVID-19 with a site in Switzerland, or all of them as a file.
02

Study summary

In this study, a patient space occupied by a patient with confirmed COVID-19 in an open-space multiple bed area in the Intermediate Care Unit will be equipped with a mobile, optimally placed high efficiency particulate air ("HEPA")-equivalent air filtration unit ("Baldachin") in addition to existing hospital policy infection prevention and control measures. The investigators are going to evaluate this intervention regarding its capacity to prevent the nosocomial onwards transmission of Sars-COV2 to patients located in the same multiple-bed open space patient area.

Read the detailed description

SARS-CoV-2 transmission includes a considerable amount of long-distance aerosol transmission. Ideal isolation is in single rooms. Isolation in special care multiple bed open-space patient areas (e.g. in the Intensive and Intermediate Care Unit) is set back to onsite isolation with distancing and ventilation as partial mitigation measures against nosocomial transmission.

The investigators want to assess the effect of supplementation of existing room ventilation by means of an optimally placed mobile high efficiency particulate air ("HEPA") filtration unit ("Baldachin") in the ceiling area over confirmed COVID-19 infected patients on nosocomial onwards transmission to patients located in the same open-space multiple bed area. In order to quantify the effect, the investigators will determine the proportion of nosocomially infected individuals as assessed by nasopharyngeal swab on day 4 after the last exposure amongst all in the same room exposed patients in cardiovascular open-space Intermediate Care Unit rooms with "Baldachin" vs. open-space Intermediate Care Unit rooms without "Baldachin".

03

Conditions studied

  • COVID-19

Keywords

  • Sars-CoV2
  • Aerosols
  • Infection transmission
  • Infection risk
  • Respiratory Tract Infections
  • Virus Diseases
04

Who can participate

Ages eligible
18 Years to 120 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult inpatients of included open-space IMC units with lab-confirmed SARS-CoV-2 infection, symptom onset or date of test ≤10 days prior inclusion.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy, unability to give consent (e.g. form not available in patient language or non-judicious)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
104 participants (estimated)

Study arms

  • No intervention
    Standard of Care

    Patients exposed to a patient with COVID-19 isolated at the site - standard of care

  • Active comparator
    Baldachin-Intervention

    Patients exposed to a patient with COVID-19 isolated at the site - under Baldachin

    Device: Baldachin

Interventions

  • DeviceBaldachin

    Environmental intervention: Equipment of a patient space of a patient with confirmed COVID-19 in open-space multiple bed Intermediate Care Unit areas with a mobile, optimally placed high efficiency particulate air ("HEPA")-equivalent air filtration unit ("Baldachin") in addition to existing room ventilation and hospital policy infection prevention and control measures.

06

What researchers measure

Primary outcomes

  1. Proportion of nosocomially infected individuals within 4 days after exposure

    Assessed by nasopharyngeal swab on day 4 after the last exposure amongst all in the same room exposed patients in cardiovascular open-space Intermediate Care Unit ("IMC") rooms with the environmental interventions vs. open-space IMC rooms without the environmental intervention

    Time frame: 4 days after last exposure

Secondary outcomes

  1. Exposure duration

    Expected to be on average hours up to a few days

    Time frame: Period when exposed to a patient with confirmed COVID-19 in the same room

  2. Proportion of immunocompromised patients among those exposed

    e.g. patients under treatment with steroids, chemotherapy

    Time frame: At the time of exposure

  3. Preexisting air change rate per hour in the rooms where exposure occurs

    Time frame: At the time of exposure

  4. Age of exposed patients

    As part of the demographic characteristics

    Time frame: At the time of exposure

  5. Gender of exposed patients

    As part of the demographic characteristics

    Time frame: At the time of exposure

  6. Proportion of nosocomially infected patients within 10 days after exposure

    As documented in the electronic patient record

    Time frame: 10 days after last exposure

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Nov 2024, 14 months after the start.

Of 1,337 non-industry interventional studies with no phase under COVID-19, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 20. This study's planned 14 months is above that.

Counting every sponsor, half of 1,475 studies reached it within 9 months; a quarter within 3 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2022
First posted
Dec 13, 2022
StartActual
Sep 13, 2023
Primary completionEst.
Nov 30, 2024
CompletionEst.
Nov 30, 2024
Last update
Dec 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05648097
Responsible party
Sponsor
First posted
Dec 13, 2022
Start date
Sep 13, 2023
Primary completion
Nov 30, 2024 (estimated)
Completion
Nov 30, 2024 (estimated)
Last update
Dec 6, 2023

Study contacts

Philipp Jent, MD
Contact
philipp.jent@insel.ch
+41 31 632 99 92
Karin J Grimm, MD
Contact
KarinJanina.Grimm@insel.ch
+41 31 63 2 76 85
Philipp Jent, MD
principal investigator · Department of Infectious Diseases Inselspital Bern University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion